Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Contraceptive Patch Maker Agile Recapitalizes With $45 Million Venture Round

This article was originally published in The Pink Sheet Daily

Executive Summary

Agile said in 2008 its lead product was ready for Phase III trials. Those trials might start soon, now that the firm has found new backers.
Advertisement

Related Content

Transdermal Delivery Trumps Advisory Panel Concerns About Blood Clots With J&J’s Ortho Evra
Financings Of The Fortnight Follows The Money Wherever It Goes
Financings Of The Fortnight Follows The Money Wherever It Goes
Agile’s Low-Dose Birth Control Patch Heads For Phase III
Agile’s Low-Dose Birth Control Patch Heads For Phase III
Public Citizen Demands Removal of J&J’s Ortho Evra Patch From Marketplace

Topics

Advertisement
UsernamePublicRestriction

Register

PS070755

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel